| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/06/2011 | US20110003793 AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF |
| 01/06/2011 | US20110003787 Novel phenylpyrrole derivative |
| 01/06/2011 | US20110003785 Fused Thiazole Derivatives As Kinase Inhibitors |
| 01/06/2011 | US20110003783 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| 01/06/2011 | US20110003782 23-Substituted Bile Acids as TGR5 Modulators and Methods of Use Thereof |
| 01/06/2011 | US20110003774 Compounds having anti-proliferative properties |
| 01/06/2011 | US20110003772 Use of sphingolipids in the treatment of type 2 diabetes mellitus, insulin resistance and metabolic syndrome |
| 01/06/2011 | US20110003762 Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| 01/06/2011 | US20110003759 Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| 01/06/2011 | US20110003756 C5a Receptor Antagonists |
| 01/06/2011 | US20110003746 Protein variants |
| 01/06/2011 | US20110003741 Novel neurturin conjugates for pharmaceutical use |
| 01/06/2011 | US20110003740 Insulin sensitisers and methods of treatment |
| 01/06/2011 | US20110003739 Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| 01/06/2011 | US20110003738 Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
| 01/06/2011 | US20110003737 Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| 01/06/2011 | US20110003388 processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient; making an enhanced, autologous fat graft comprising supplementing a first portion of extracted adipose tissue with an additive and a disaggregated population of adipose-derived cells |
| 01/06/2011 | US20110003360 Delta-6 desaturase and uses thereof |
| 01/06/2011 | US20110003351 Delta-5 desaturase and uses thereof |
| 01/06/2011 | US20110003013 Method of increasing metabolism |
| 01/06/2011 | US20110002994 Method of regulating the th17 pathway and its associated metabolic impact |
| 01/06/2011 | US20110002984 Formulations comprising exine shells |
| 01/06/2011 | US20110002983 Compound |
| 01/06/2011 | US20110002955 Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same |
| 01/06/2011 | US20110002952 FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF |
| 01/06/2011 | US20110002943 Use of enterovirus for diagnostics, treatment and prevention of disease |
| 01/06/2011 | US20110002939 monoclonal antibody and a method thereof |
| 01/06/2011 | US20110002931 Bispecific antibodies that bind to complement proteins |
| 01/06/2011 | US20110002928 Uses of Mammalian Cytokine; Related Reagents |
| 01/06/2011 | US20110002910 Therapeutic agents comprising pro-apoptotic proteins |
| 01/06/2011 | US20110002908 Treatment of a-galactosidase a deficiency |
| 01/06/2011 | US20110002906 Purification and Isolation of Recombinant Oxalate Degrading Enzymes and Spray-Dried Particles Containing Oxalate Degrading Enzymes |
| 01/06/2011 | US20110002902 Inhibitor for blood phosphorus level elevation |
| 01/06/2011 | US20110002900 Medium chain dicarboxylic acids, their derivates and metabolic disorders |
| 01/06/2011 | US20110002896 Methods and related compositions for reduction of fat |
| 01/06/2011 | US20110002888 Albumin Fusion Proteins |
| 01/06/2011 | US20110002876 Multimeric VLA-4 Antagonists Comprising Polymer Moieties |
| 01/06/2011 | US20110002855 Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues |
| 01/06/2011 | CA2766095A1 Composition and method for reducing food intake |
| 01/05/2011 | EP2270049A2 Recombinant anti-interleukin-9-antibody |
| 01/05/2011 | EP2270042A2 KDR peptides and vaccines comprising the same |
| 01/05/2011 | EP2270041A2 KDR peptides and vaccines comprising the same |
| 01/05/2011 | EP2270007A1 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| 01/05/2011 | EP2270005A1 Prodrug of an ice inhibitor |
| 01/05/2011 | EP2269988A2 Anthranilic acid amides and pharmaceutical use thereof |
| 01/05/2011 | EP2269977A2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| 01/05/2011 | EP2269656A2 Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment |
| 01/05/2011 | EP2269654A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 01/05/2011 | EP2269646A1 Prophylactic or therapeutic agent for diabetes or obesity |
| 01/05/2011 | EP2269628A2 Pancreas-specific proteins |
| 01/05/2011 | EP2269620A1 Therapeutic uses of dunaliella powder |
| 01/05/2011 | EP2269613A2 Solid orald dosage form comprising a combination of metformin and glibenclamide |
| 01/05/2011 | EP2269610A2 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| 01/05/2011 | EP2269601A1 LR-9, LR-74 and LR-90 for use in treating complications resulting from diabetes |
| 01/05/2011 | EP2269590A2 Ion binding polymers and uses thereof |
| 01/05/2011 | EP2269589A2 Ion binding polymers and uses thereof |
| 01/05/2011 | EP2268653A2 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds, and the use thereof |
| 01/05/2011 | EP2268641A2 Heterocyclic compounds as adenosine receptor antagonist |
| 01/05/2011 | EP2268637A1 Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors |
| 01/05/2011 | EP2268633A1 Pyridazinone glucokinase activators |
| 01/05/2011 | EP2268606A1 4-dimethylaminobutyric acid derivatives |
| 01/05/2011 | EP2094706B1 Substituted 2,5-dfflydro-3h-pyrazolo[4,3-c]pyridazin-3-one derivatives, preparation thereof and use of same as cannabinoid cb1 receptor ligands |
| 01/05/2011 | EP1789026B1 Method for systemic bio-correction of an organism |
| 01/05/2011 | EP1661890B1 Ppar-activating compound and pharmaceutical composition containing same |
| 01/05/2011 | EP1465637B1 25-hydroxy vitamin d3 compositions |
| 01/05/2011 | EP1446381B1 Anthranilic acid amides and pharmaceutical use thereof |
| 01/05/2011 | EP1437043B1 Rat model with overexpression of regucalcin |
| 01/05/2011 | EP1307218B1 Treatment of obesity |
| 01/05/2011 | EP0815129B1 Ingap protein involved in pancreatic islet neogenesis |
| 01/05/2011 | CN101939338A 1b20 pcsk9 antagonists |
| 01/05/2011 | CN101939313A 3,8-diaminotetrahydroquinoline derivative |
| 01/05/2011 | CN101939027A Lipopeptides for delivery of nucleic acids |
| 01/05/2011 | CN101939022A Methods for treating obesity and obesity related diseases and disorders |
| 01/05/2011 | CN101938911A Protein-dense micellar casein-based liquid enteral nutritional composition |
| 01/05/2011 | CN101935656A Gene for promoting insulin secretion, preparation method and application thereof |
| 01/05/2011 | CN101935623A Agrobacterium ZX09, water-soluble beta-glucan prepared from Agrobacterium ZX09 and preparation method thereof and application on reducing blood sugar |
| 01/05/2011 | CN101935359A Liriope muscari baily polysaccharide and preparation method thereof |
| 01/05/2011 | CN101935349A Humanized monoclonal antibody against human vascular endothelial growth factor and preparation and application thereof |
| 01/05/2011 | CN101935346A Mutated human-source fibroblast growth factor and application in treating endocrine diseases |
| 01/05/2011 | CN101935334A Berberine glycyrrhetinic acid enantiomeric salts and preparation method and application thereof |
| 01/05/2011 | CN101935301A Modulators of ATP-binding cassette transporters |
| 01/05/2011 | CN101935274A Process for producing medicinal zinc citrate |
| 01/05/2011 | CN101934036A Method for preparing medicament for treating diabetes mellitus |
| 01/05/2011 | CN101934032A Chinese medicinal compound external preparation for treating diabetes and preparation method and application thereof |
| 01/05/2011 | CN101934030A Medicinal composition for treating symptom-complex of excessive eating (diabetes) and method for preparing same |
| 01/05/2011 | CN101933990A Application of galium verum L. general flavone in preparing medicicament of alpha-glucuronide inhibitor |
| 01/05/2011 | CN101933988A Hawthorne leaf extract chewable tablet and preparation method thereof |
| 01/05/2011 | CN101933965A Mugwort extract and preparation process thereof, and application in controlling postmeal gucose |
| 01/05/2011 | CN101933952A Medicinal composition with raw materials comprising fermented cordyceps mycelium powder, D-ribose and honey |
| 01/05/2011 | CN101933945A Medicinal composition taking salidroside, D-ribose and honey as raw materials |
| 01/05/2011 | CN101933944A Method for preparing bone peptide injection |
| 01/05/2011 | CN101933922A Amino acid composition containing new antioxidant |
| 01/05/2011 | CN101933919A Application of brown cyanidin |
| 01/05/2011 | CN101647820B Active pure snake powder capsule and preparation technique thereof |
| 01/05/2011 | CN101623271B Compound alpha-keto acid dispersible tablet |
| 01/05/2011 | CN101584682B Rutin-arabic-gum-gelatin slowreleasing microspheres and preparation thereof |
| 01/05/2011 | CN101537160B Health product for toxicant elimination and beauty maintenance |
| 01/05/2011 | CN101417077B Compound buckwheat flower and leaf flavones preparation for controlling diabetes and complicating disease thereof and preparation method thereof |
| 01/04/2011 | US7863475 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active |
| 01/04/2011 | US7863302 Compounds and methods for modulating FX-receptors |